- Home
- JXG vs AIMD Comparison
JXG vs AIMD Comparison
Compare JXG & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXG
- AIMD
- Stock Information
- Founded
- JXG N/A
- AIMD 1984
- Country
- JXG China
- AIMD United States
- Employees
- JXG N/A
- AIMD N/A
- Industry
- JXG
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- JXG
- AIMD Health Care
- Exchange
- JXG Nasdaq
- AIMD Nasdaq
- Market Cap
- JXG 16.9M
- AIMD 16.9M
- IPO Year
- JXG N/A
- AIMD N/A
- Fundamental
- Price
- JXG $0.79
- AIMD $3.62
- Analyst Decision
- JXG
- AIMD
- Analyst Count
- JXG 0
- AIMD 0
- Target Price
- JXG N/A
- AIMD N/A
- AVG Volume (30 Days)
- JXG 388.4K
- AIMD 64.2K
- Earning Date
- JXG 12-05-2025
- AIMD 11-14-2025
- Dividend Yield
- JXG N/A
- AIMD N/A
- EPS Growth
- JXG N/A
- AIMD N/A
- EPS
- JXG 0.86
- AIMD N/A
- Revenue
- JXG $49,840,288.00
- AIMD $110,870.00
- Revenue This Year
- JXG N/A
- AIMD N/A
- Revenue Next Year
- JXG N/A
- AIMD N/A
- P/E Ratio
- JXG $0.96
- AIMD N/A
- Revenue Growth
- JXG 56.53
- AIMD 70.25
- 52 Week Low
- JXG $0.55
- AIMD $2.00
- 52 Week High
- JXG $6.52
- AIMD $5.00
- Technical
- Relative Strength Index (RSI)
- JXG 38.83
- AIMD 46.66
- Support Level
- JXG $0.85
- AIMD $3.39
- Resistance Level
- JXG $0.94
- AIMD $3.75
- Average True Range (ATR)
- JXG 0.07
- AIMD 0.24
- MACD
- JXG -0.01
- AIMD -0.06
- Stochastic Oscillator
- JXG 0.00
- AIMD 21.90
About JXG JX Luxventure Limited Common Stock
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.